HEALEY ALS Trial Serves Up More Disappointment as Denali, AbbVie/Calico Fail
Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the latest setbacks for the controversial platform trial, the results from which have largely mirrored the dismal success rate in the ALS space overall.
STAT reporters discuss why a looming patent cliff could lead to more pharmaceutical deal-making and a new obesity startup.
Calico Life Sciences, a biotech founded by Alphabet and Arthur Levinson focused on the biology of aging and age-related ...
Google’s ( GOOGL) anti-aging company Calico released disappointing trial results of its first ever drug.
The company said Monday that fosigotifator failed to outperform placebo in slowing the neurodegenerative disease, but is ...
AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...
Small businesses in Los Angeles and the surrounding counties have offered help to people affected by the fires raging in the ...
Twelve years after launching the successful Maple Street Biscuit Co. chain, co-founder Scott Moore is set to debut a new and ...
Hosted on MSN2d
Fierce bird attacks calico cat lurking under its treeA fierce bird attacked a calico cat lurking under its tree territory. Footage shows the oriental magpie robin swooping down ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback